Matching Items (6)
Filtering by

Clear all filters

136012-Thumbnail Image.png
Description
Bexarotene is a commercially produced drug commonly known as Targetin presecribed to treat cutaneous T-cell lymphoma (CTCL). Bex mimics the actions of natural 9-cis retinoic acid in the body, which are derived from Vitamin A in the diet and boost the immune system. Bex has been shown to be effective

Bexarotene is a commercially produced drug commonly known as Targetin presecribed to treat cutaneous T-cell lymphoma (CTCL). Bex mimics the actions of natural 9-cis retinoic acid in the body, which are derived from Vitamin A in the diet and boost the immune system. Bex has been shown to be effective in the treatment of multiple types of cancer, including lung cancer. However, the disadvantages of using Bex include increased instances of hypothyroidism and excessive concentrations of blood triglycerides. If an analog of Bex can be developed which retains high affinity RXR binding similar to the 9-cis retinoic acid while exhibiting less interference for heterodimerization pathways, it would be of great clinical significance in improving the quality of life for patients with CTCL. This thesis will detail the biological profiling of additional novel (Generation Two) analogs, which are currently in submission for publication, as well as that of Generation Three analogs. The results from these studies reveal that specific alterations in the core structure of the Bex "parent" compound structure can have dramatic effects in modifying the biological activity of RXR agonists.
ContributorsYang, Joanna (Author) / Jurutka, Peter (Thesis director) / Wagner, Carl (Committee member) / Hibler, Elizabeth (Committee member) / Barrett, The Honors College (Contributor)
Created2012-05
136167-Thumbnail Image.png
Description
Bexarotene (Targretin®) is an FDA approved drug used to treat cutaneous T-cell lymphoma (CTCL), as well as off-label treatments for various cancers and neurodegenerative diseases. Previous research has indicated that bexarotene has a specific affinity for retinoid X receptors (RXR), which allows bexarotene to act as a ligand-activated-transcription factor

Bexarotene (Targretin®) is an FDA approved drug used to treat cutaneous T-cell lymphoma (CTCL), as well as off-label treatments for various cancers and neurodegenerative diseases. Previous research has indicated that bexarotene has a specific affinity for retinoid X receptors (RXR), which allows bexarotene to act as a ligand-activated-transcription factor and in return control cell differentiation and proliferation. Bexarotene targets RXR homodimerization to drive transcription of tumor suppressing genes; however, adverse reactions occur simultaneously when bound to other nuclear receptors. In this study, we used novel bexarotene analogs throughout 5 iterations synthesized in the laboratory of Dr. Wagner to test for their potency and ability to bind RXR. The aim of our study is to quantitatively measure RXR homodimerization driven by bexarotene analogs using a yeast two-hybrid system. Our results suggests there to be several compounds with higher protein activity than bexarotene, particularly in generations 3.0 and 5.0. This higher affinity for RXR homodimers may help scientists identify a compound that will minimize adverse effects and toxicity of bexarotene and serve as a better cancer treatment alternative.
ContributorsSeto, David Hua (Author) / Marshall, Pamela (Thesis director) / Wagner, Carl (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Natural Sciences (Contributor) / School of Social and Behavioral Sciences (Contributor)
Created2015-05
ContributorsYoung, Macy (Author) / Biviji, Rizwana (Thesis director) / Ohri-Vachaspati, Punam (Committee member) / Acciai, Francesco (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Natural Sciences (Contributor) / College of Health Solutions (Contributor)
Created2023-05
ContributorsYoung, Macy (Author) / Biviji, Rizwana (Thesis director) / Ohri-Vachaspati, Punam (Committee member) / Acciai, Francesco (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Natural Sciences (Contributor) / College of Health Solutions (Contributor)
Created2023-05
Description

The ever-increasing importance of cancer and neurodegenerative diseases continues to grow as populations across the world are affected by death and aging. The vitamin A (RXR) and vitamin D (VDR) receptor pathways offer promising potential to aid in treatment of cancer and Alzheimer’s disease. This thesis discusses the potential application

The ever-increasing importance of cancer and neurodegenerative diseases continues to grow as populations across the world are affected by death and aging. The vitamin A (RXR) and vitamin D (VDR) receptor pathways offer promising potential to aid in treatment of cancer and Alzheimer’s disease. This thesis discusses the potential application of novel analogs of Bexarotene (RXR agonist), MeTC7 (a new potent VDR antagonist), and vitamin D as possible therapeutics for cancer and Alzheimer’s disease.

ContributorsHong, Jennifer (Author) / Jurutka, Peter (Thesis director) / Wagner, Carl (Committee member) / Marshall, Pamela (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Natural Sciences (Contributor)
Created2023-05
Description

Background: Recent studies have shown a decline in birth rates in large metropolitan areas (after accounting for population), which can be possibly explained by barriers to reproduction associated with the COVID-19 pandemic and related lockdowns. Objective: This study’s objective was to investigate the impact of the COVID-19 pandemic and related

Background: Recent studies have shown a decline in birth rates in large metropolitan areas (after accounting for population), which can be possibly explained by barriers to reproduction associated with the COVID-19 pandemic and related lockdowns. Objective: This study’s objective was to investigate the impact of the COVID-19 pandemic and related lockdowns on the fertility rates of women in reproductive ages living in Greater Phoenix. Methods: The total number of inpatient births and people in both Maricopa and Pinal Counties during pre-COVID-19 years (2017-2019) were compared with those during the COVID-19 years (2021) among women in reproductive ages (15-49 years). To make age-specific comparisons, women in reproductive years were divided into eight distinct age group categories (15-17, 18-20, and then five year age group categories to age 49) from which age-specific, general, and total fertility rates were calculated. Results: Using a two-sample z-test for difference in proportions, findings revealed that the general fertility rate in Greater Phoenix had significantly declined from 48 to 46 per 1,000 population from the pre-COVID-19 period to COVID-19 period (P<0.001). Two sample z-tests were also used to compare age-specific fertility rates, which revealed a significant decline in the fertility rate in women ages 15-17 (from 8.0/1000 to 5.0/1000) (P<0.001), 18-20 (from 43.0/1000 to 35.0/1000) (P<0.001), and 21-24 (from 79.0/1000 to 68.0/1000) (P<0.001) from the pre-COVID-19 period to COVID-19 period, while no significant change was observed in the fertility rate in women ages 25-49. Conclusions: The observed general fertility decline in Greater Phoenix as a result of the COVID-19 pandemic poses significant implications for further research on barriers to reproduction brought upon by the COVID-19 pandemic and related lockdown measures. Another direction for further research involves possibly continuing this study to include years 2022 and 2023 in the COVID-19 period, as well as calculating age-specific fertility rates by race.

ContributorsYoung, Macy (Author) / Biviji, Rizwana (Thesis director) / Ohri-Vachaspati, Punam (Committee member) / Acciai, Francesco (Committee member) / Barrett, The Honors College (Contributor) / School of Mathematical and Natural Sciences (Contributor) / College of Health Solutions (Contributor)
Created2023-05